Skip to main content

Table 4 One-way sensitivity analysis

From: Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis

  Continuous CB Second line LC Difference ICER (€/QALY gained)
BASE CASE     
  QALYs 4,579 4,653 73.88 Dominant
  Costs (thousands) €5,044 1,169 - €3,875
SA1 Time horizon (5 years)     
  QALYs 2,555 2,580 25.50 Dominant
  Costs (€ thousand) €2,452 €835 - €1,616
SA2 Time horizon (10 years)     
  QALYs 3,711 3,760 48.67 Dominant
  Costs (€ thousand) €3,920 €1,028 - €2,892
SA3 Included unrelated future dialysis costs    
  QALYs 4,579 4,653 73.88 €45,557
  Costs (€ thousand) €127,149 €130,515 €3,336
SA4 Dialysis target level 5 mg/dL    
  QALYs 4,579 4,658 79.30 Dominant
  Costs (€ thousand) €5,044 €1,383 - €3,661
S5 Annual Discount Rate (6%)    
  QALYs 3,846 3,903 56.95 Dominant
  Costs (€ thousand) €4,122 €1,036 - €3,086
S6 Annual Discount Rate (0%)    
  QALYs 5,598 5,498 99.48 Dominant
  Costs (€ thousand) €6,346 €1,348 - €4,999
S7 Only considering Acetate carbonate    
  QALYs 4,643 4,713 69.54 Dominant
  Costs (€ thousand) €4,906 €1,324 - €3,582
S8 Only considering Calcium carbonate    
  QALYs 4,511 4,590 79.02 Dominant
  Costs (€ thousand) €5,223 €1,025 - €4,198
S9 Dialysis mortality from Block 1998     
  QALYs 4,571 4,620 49.51 Dominant
  Costs (€ thousand) €4,840 €1,170 -€3,670  
S10 Without utility decrement for vomiting     
  QALYs 4,579 4,653 73.93 Dominant
  Costs (€ thousand) €5,044 1,169 - €3,875  
  1. CA: calcium acetate; CB: Calcium Binder; CC: calcium carbonate; ICER: Incremental cost-effectiveness ratio; LC: lanthanum carbonate; QALY: Quality Adjusted Life Year.